Biomarker may predict who'll benefit from targeted therapy for HER2-negative breast c

[News]

A multicenter team led by Case Western Reserve has demonstrated that brief exposure to a targeted therapy can tell doctors which HER2-negative patients will respond -- and which should switch to...

More... (http://www.medicalnewstoday.com/releases/299728.php)